Table 5.
Effect of ever versus never* using angiotensin receptor blocker (ARB), stratified by first specific drug used, on risk of specific cancers
| Specific drug | Hazard ratio (95% CI) |
|---|---|
| Any cancer | |
| Losartan | 1.04 (0.98 to 1.09) |
| Candesartan | 1.04 (0.98 to 1.11) |
| Irbesartan | 1.02 (0.95 to 1.09) |
| Valsartan | 1.04 (0.96 to 1.12) |
| Telmisartan | 0.99 (0.87 to 1.14) |
| Other | 0.97 (0.85 to 1.10) |
| Lung cancer | |
| Losartan | 0.84 (0.70 to 1.00) |
| Candesartan | 0.99 (0.81 to 1.21) |
| Irbesartan | 0.71 (0.55 to 0.93) |
| Valsartan | 0.90 (0.70 to 1.16) |
| Telmisartan | 0.78 (0.48 to 1.25) |
| Other | 0.60 (0.36 to 1.02) |
| Breast cancer | |
| Losartan | 1.04 (0.91 to 1.19) |
| Candesartan | 1.07 (0.90 to 1.26) |
| Irbesartan | 1.11 (0.92 to 1.33) |
| Valsartan | 1.19 (0.99 to 1.44) |
| Telmisartan | 1.36 (1.00 to 1.86) |
| Other | 1.34 (0.99 to 1.81) |
| Prostate cancer | |
| Losartan | 0.98 (0.85 to 1.13) |
| Candesartan | 1.32 (1.13 to 1.54) |
| Irbesartan | 1.04 (0.86 to 1.27) |
| Valsartan | 1.17 (0.97 to 1.43) |
| Telmisartan | 1.03 (0.72 to 1.47) |
| Other | 0.96 (0.67 to 1.37) |
| Colon cancer | |
| Losartan | 1.14 (0.96 to 1.37) |
| Candesartan | 0.89 (0.70 to 1.14) |
| Irbesartan | 1.08 (0.85 to 1.39) |
| Valsartan | 0.93 (0.70 to 1.24) |
| Telmisartan | 0.90 (0.54 to 1.51) |
| Other | 0.95 (0.59 to 1.54) |
*Comparison group was patients who had taken only ACE inhibitor.